The Lancet · Online First· Bo Lan, Yehui Shi, Xiying Shao, Fan Wu, Shusen Wang, Weimin Xie, Qingyuan Zhang, Quchang Ouyang, Jiuwei Cui, Xiaoling Ling, Haijun Yu, Huihui Li, Xianjun Tang, Sijuan Ding, Chunfang Hao, Bing Zhao, Yang Li, Hua Yang, Min Yan, Guohui Han, Xujuan Wang, Fanfan Li, Peijian Peng, Chang Gong, Yunjiang Liu, Junlan Guo, Yongmei Yin, Man Li, Yue’e Teng, Jiuda Zhao, Yongli Gao, Jingfen Wang, Jing Luo, Xinghua Han, Xiaoping Li, Bin Liu, Shuqun Zhang, Bihui Li, Lei Yang, Sa Xiao, Hai Zhu, Yi Zhu, Binghe Xu, PANKU-Breast01 Investigators·· 4 小时前精选AI 评分60
PANKU-Breast01 III 期试验：Izalontamab brengitecan 改善中国 HR+/HER2– 乳腺癌患者无进展生存期
[Articles] Izalontamab brengitecan for HR+/HER2– breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial
AI 导读
PANKU-Breast01 随机 III 期临床试验显示，Izalontamab brengitecan（iza-bren）较化疗显著改善中国既往接受治疗的 HR+/HER2– 乳腺癌患者的无进展生存期。
推荐理由
该试验为多线治疗后的患者提供了与化疗比较的无进展生存期证据，但总生存期数据尚不成熟，尚未确立总生存获益。
来源：The Lancet · Online First · thelancet.com